公开(公告)号：US20230346804A1

公开(公告)日：2023-11-02

申请号：US18141805

申请日：2023-05-01

申请人： EIRGEN PHARMA LTD

发明人： Eric J. Messner ,  P. Martin Petkovich ,  Jay A. White ,  Samir P. Tabash ,  Joel Z. Melnick ,  Charles W. Bishop

IPC分类号： A61K31/593 ,  A61K31/592 ,  A61K9/48

CPC分类号： A61K31/593 ,  A61K31/592 ,  A61K9/4858

摘要： Methods and compositions for reducing serum parathyroid levels in, for example, chronic kidney disease patients are disclosed. In these methods, an effective amount of a modified release formulation of 25-hydroxyvitamin D is orally administered to a patient suffering from secondary hyperparathyroidism to lower the patient's serum intact parathyroid hormone (iPTH) level, while avoiding a surge in serum total 25-hydroxyvitamin D.

公开(公告)号：US20210308151A1

公开(公告)日：2021-10-07

申请号：US17223631

申请日：2021-04-06

申请人： EIRGEN PHARMA LTD.

发明人： Charles W. Bishop ,  Stephen A. Strugnell ,  Akhtar Ashfaq ,  Reem Elamein Elsiddig ,  Colm Nulty

IPC分类号： A61K31/593 ,  A61K9/00 ,  A61P31/14

摘要： Provided herein are methods of treating COVID-19 in a subject in need thereof, comprising administering to the subject a 25-hydroxyvitamin D compound. Also provided herein are hard capsule dosage forms of 25-hydroxyvitamin. In aspects, the 25-hydroxyvitamin D is administered as a controlled release formulation, optionally an extended release oral formulation, such as Rayaldee® extended release calcifediol capsules. Methods of treating SARS-CoV-2 infection including reducing SARS-CoV-2 viral load are provided. Methods of treating SARS-CoV-2 infection including increasing an immune response are provided.

公开(公告)号：US20220226351A1

公开(公告)日：2022-07-21

申请号：US17429278

申请日：2020-02-06

申请人： EIRGEN PHARMA LTD.

发明人： Charles W. Bishop

IPC分类号： A61K31/592 ,  A61K31/593 ,  A61P5/18 ,  A61P3/02

摘要： Methods and compositions for controlling hyperparathyroidism are disclosed.

公开(公告)号：US20210260079A1

公开(公告)日：2021-08-26

申请号：US17317823

申请日：2021-05-11

申请人： EIRGEN PHARMA LTD.

发明人： P. Martin Petkovich ,  Joel Z. Melnick ,  Jay A. White ,  Samir P. Tabash ,  Charles W. Bishop ,  Susan Peers ,  Stephen A. Strugnell

IPC分类号： A61K31/593 ,  A61K31/592 ,  A61K9/00 ,  A61K47/26 ,  A61K9/48 ,  A61K31/675 ,  A61K39/395 ,  A61K31/135 ,  A61K31/663 ,  A61K47/44 ,  A61K31/137 ,  A61K45/06 ,  A61K47/06 ,  A61K47/14 ,  A61K47/38

摘要： Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

公开(公告)号：US11738033B2

公开(公告)日：2023-08-29

申请号：US17317823

申请日：2021-05-11

申请人： EIRGEN PHARMA LTD.

发明人： P. Martin Petkovich ,  Joel Z. Melnick ,  Jay A. White ,  Samir P. Tabash ,  Charles W. Bishop ,  Susan Peers ,  Stephen A. Strugnell

IPC分类号： A61K31/593 ,  A61K31/592 ,  A61K9/00 ,  A61K47/26 ,  A61K9/48 ,  A61K31/675 ,  A61K39/395 ,  A61K31/135 ,  A61K31/663 ,  A61K47/44 ,  A61K31/137 ,  A61K45/06 ,  A61K47/06 ,  A61K47/14 ,  A61K47/38 ,  A61K39/00

CPC分类号： A61K31/593 ,  A61K9/0019 ,  A61K9/0053 ,  A61K9/4825 ,  A61K9/4875 ,  A61K31/135 ,  A61K31/137 ,  A61K31/592 ,  A61K31/663 ,  A61K31/675 ,  A61K39/395 ,  A61K45/06 ,  A61K47/06 ,  A61K47/14 ,  A61K47/26 ,  A61K47/38 ,  A61K47/44 ,  A61K2039/505 ,  C07K2317/21 ,  C07K2317/76 ,  A61K31/663 ,  A61K2300/00 ,  A61K31/593 ,  A61K2300/00 ,  A61K31/592 ,  A61K2300/00 ,  A61K31/137 ,  A61K2300/00 ,  A61K39/395 ,  A61K2300/00 ,  A61K31/675 ,  A61K2300/00 ,  A61K31/675 ,  A61L2300/00

摘要： Methods, compositions, and kits for adjunctive therapy using 25-hydroxyvitamin D are disclosed. The 25-hydroxyvitamin D may be administered with an agent that increases the risk of hypocalcemia, such as cinacalcet or a salt thereof, and/or an anticancer agent. The adjunctive therapy is effective to treat and prevent iatrogenic hypocalcemia and/or secondary hyperparathyroidism, as well as delay cancer progression and the time to a post-treatment skeletal related event.

公开(公告)号：US20220062304A1

公开(公告)日：2022-03-03

申请号：US17498496

申请日：2021-10-11

申请人： EIRGEN PHARMA LTD.

发明人： Joel Z. Melnick ,  Charles W. Bishop ,  P. Martin Petkovich ,  Stephen A. Strugnell

IPC分类号： A61K31/593 ,  A61K31/592 ,  A61P3/02 ,  A61P13/12 ,  A61K9/00

摘要： Methods for treating vitamin D insufficiency and secondary hyperparathyroidism in patients having CKD comprising administering repeat doses of 25-hydroxyvitamin D are disclosed. The methods comprise administering 25-hydroxyvitamin D in an amount effective to safely raise the patient's serum 25-hydroxyvitamin D level to greater than 90 ng/ml and/or to control the patient's serum ratio of 25-hydroxyvitamin D to 24,25-dihydroxyvitamin D to less than 20.